In addition, mice with disruption of STING in macrophages exhibited less hepatic steatosis, inflammation and fibrosis after high-fat diet or MASH diet feeding, suggesting that the STING pathway may be a therapeutic target for MASLD [132]. Here, STING1 is linked to metabolic dysfunction-associated steatotic liver disease.